https://www.selleckchem.com/EGFR(HER).html
BACKGROUND The influenza A(H3N2) vaccine was updated from clade 3C.3a in 2015-16 to a clade 3C.2a strain for both 2016-17 and 2017-18. Circulating 3C.2a viruses showed considerable diversity in the hemagglutinin glycoprotein and the egg-adapted vaccine strain also bore mutations, notably T160K loss-of-glycosylation. METHODS Vaccine effectiveness (VE) in 2016-17 and 2017-18 was assessed by test-negative-design, explored by A(H3N2) phylogenetic sub-cluster and prior season's vaccination history. RESULTS In 2016-17, A(H3N2) VE was 36%(95%CI=18-50
Beğen
Yorum Yap
Paylaş
